- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT01297504
A One-Year Observation of Palivizumab in Infants at Risk for Respiratory Syncytial Virus Infection in Latin America
A One-Year Observational Study of Palivizumab in Infants at Risk for Respiratory Syncytial Virus Infection in Latin America
Studienübersicht
Status
Bedingungen
Detaillierte Beschreibung
RSV causes significant disease. There is a paucity of data from developing countries even though existing data clearly indicate that RSV accounts for a high proportion of acute respiratory illnesses (ARIs) in children.
This is a multi-center study in a cohort of infants at risk for RSV infection in Latin America who have received palivizumab in the usual manner in accordance with the terms of marketing authorization with regard to dose, population and indication. Enrolled participants were followed for one year after their first dose of palivizumab. Epidemiological and clinical data as well as information about compliance, hospitalizations and safety was collected.
Studientyp
Einschreibung (Tatsächlich)
Kontakte und Standorte
Studienorte
-
-
-
Buenos Aires, Argentinien, C1115AAB
- Site Reference ID/Investigator# 52185
-
Buenos Aires, Argentinien
- Site Reference ID/Investigator# 52182
-
Buenos Aires, Argentinien
- Site Reference ID/Investigator# 52183
-
Buenos Aires, Argentinien
- Site Reference ID/Investigator# 52184
-
-
-
-
-
Santiago, Chile
- Site Reference ID/Investigator# 54426
-
Santiago, Chile
- Site Reference ID/Investigator# 54427
-
-
-
-
-
Quito, Ecuador
- Site Reference ID/Investigator# 52703
-
Quito, Ecuador
- Site Reference ID/Investigator# 52704
-
-
-
-
-
Armenia, Kolumbien
- Site Reference ID/Investigator# 52732
-
Barranquilla, Kolumbien
- Site Reference ID/Investigator# 52722
-
Barranquilla, Kolumbien
- Site Reference ID/Investigator# 52726
-
Bogota, Kolumbien
- Site Reference ID/Investigator# 52723
-
Bogota, Kolumbien
- Site Reference ID/Investigator# 52725
-
Bogota, Kolumbien
- Site Reference ID/Investigator# 52727
-
Bogota, Kolumbien
- Site Reference ID/Investigator# 52729
-
Bogota, Kolumbien
- Site Reference ID/Investigator# 63882
-
Cali, Kolumbien
- Site Reference ID/Investigator# 52735
-
Medellin, Kolumbien
- Site Reference ID/Investigator# 52731
-
-
-
-
-
Guanajuato, Leon, Mexiko, CP 03700
- Site Reference ID/Investigator# 52082
-
Mexico City, DF, Mexiko, CP 04530
- Site Reference ID/Investigator# 52084
-
Nuevo Leon, Monterrey, Mexiko, CP 66480
- Site Reference ID/Investigator# 52083
-
-
-
-
-
Callao, Peru, CALLAO 2
- Site Reference ID/Investigator# 52243
-
Lima, Peru, 33
- Site Reference ID/Investigator# 52242
-
-
-
-
-
Salto, Uruguay
- Site Reference ID/Investigator# 52246
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Probenahmeverfahren
Studienpopulation
Beschreibung
Inclusion Criteria:
- Children with a history of bronchopulmonary dysplasia, infants with a history of prematurity (less than or equal to 35 weeks gestational age), or children with hemodynamically significant congenital heart disease who received the first dose of palivizumab within the 2 weeks prior to the signature of the Informed Consent Form.
- Parent or legal guardian of child provides written Informed Consent
Exclusion Criteria:
- Children excluded from receiving palivizumab as per local guidelines
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Beobachtungsmodelle: Kohorte
- Zeitperspektiven: Interessent
Kohorten und Interventionen
Gruppe / Kohorte |
---|
Palivizumab
Infants at risk for respiratory syncytial virus infection received palivizumab prescribed in accordance with the terms of the local marketing authorization.
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Characterization of Participants With Risk Factors for Respiratory Syncytial Virus (RSV) Infection
Zeitfenster: Baseline
|
Study participants were characterized at Baseline by history of bronchopulmonary dysplasia, history of prematurity (less than or equal to 35 weeks gestational age), children with hemodynamically significant congenital heart disease (CHD), the presence of cohabitants less than 6 years old, possible exposure to indoor tobacco smoke, day care attendance, asthmatic or atopic mother, smoking during pregnancy, breastfeeding, prenatal assistance (4 or more visits during pregnancy), neonatal hospitalization care, history of neonatal assisted ventilation, and mother education level (completed primary school).
|
Baseline
|
Distribution of Comorbidities in Study Participants
Zeitfenster: Baseline
|
The percentage of participants with each and combinations of the three comorbidities for which palivizumab is indicated.
|
Baseline
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Number of Participants With Hospitalizations for Lower Respiratory Tract Infection and RSV
Zeitfenster: 12 months
|
The number of participants with hospitalizations due to lower respiratory tract infection (LRTI) and hospitalizations due to lower respiratory tract infection caused by RSV.
|
12 months
|
Characterization of Hospitalization Episodes Due to Lower Respiratory Tract Infection and RSV
Zeitfenster: 12 months
|
12 months
|
|
Risk Factors for Hospitalization
Zeitfenster: Baseline and 12 months
|
Variables that could act as risk factors for hospitalization for lower respiratory tract infection were tested in univariate and multivariate Poisson regression models.
Baseline characteristics, such as age, gender, birth weight and comorbidities were included as covariates in the Poisson regression model.
Variables for multivariate analysis were added applying forward selection.
Gestational age and birth weight were included as continuous variables, considering that the higher they were the better they could act as a protection factor for hospitalization due to respiratory infection.
|
Baseline and 12 months
|
Compliance to Prescribed Palivizumab
Zeitfenster: 12 months
|
Compliance to prescribed palivizumab was calculated based on the number of doses received versus the expected number of doses for each participant.
The expected number of doses for each participant was estimated based on seasonality and current prescription guidelines for each country.
|
12 months
|
Mean Number of Doses of Palivizumab Administered
Zeitfenster: 12 months
|
12 months
|
Mitarbeiter und Ermittler
Sponsor
Mitarbeiter
Ermittler
- Studienleiter: Leandro Castillo, MD, Abbvie S.A.
Publikationen und hilfreiche Links
Nützliche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- P10-129
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Respiratory-Syncytial-Virus-Infektion
-
Janssen Vaccines & Prevention B.V.AbgeschlossenRespiratory-Syncytial-Virus-PräventionVereinigte Staaten
-
NovavaxAbgeschlossenRespiratory-Syncytial-Virus (RSV)Vereinigte Staaten
-
MedImmune LLCAbgeschlossenRespiratory-Syncytial-Virus (RSV)Vereinigte Staaten
-
AbbVieAbgeschlossen
-
University of RochesterAktiv, nicht rekrutierendRespiratory-Syncytial-Virus (RSV)Vereinigte Staaten
-
University of OxfordInnovative Medicines Initiative; Respiratory syncytial virus consortium in EuropeAktiv, nicht rekrutierendRespiratory-Syncytial-Virus (RSV)Vereinigtes Königreich
-
Enanta Pharmaceuticals, IncAbgeschlossenRespiratory-Syncytial-Virus (RSV)Vereinigte Staaten
-
GlaxoSmithKlineAbgeschlossenRespiratory-Syncytial-Virus (RSV)Belgien
-
NovavaxPATHAbgeschlossenRespiratory-Syncytial-Virus (RSV)Vereinigte Staaten
-
Enanta Pharmaceuticals, IncRekrutierungRespiratory-Syncytial-Virus (RSV)Vereinigte Staaten, Spanien, Israel, Australien, Deutschland, Korea, Republik von, Taiwan, Vereinigtes Königreich, Argentinien, Brasilien, Neuseeland, Polen, Rumänien, Südafrika, Mexiko